share_log

Bone Biologics (OTC:BBLG) and Align Technology (NASDAQ:ALGN) Critical Survey

Bone Biologics (OTC:BBLG) and Align Technology (NASDAQ:ALGN) Critical Survey

骨骼生物製劑 (OTC: BBLG) 和對齊技術 (NASDAQ: ALGN) 關鍵調查
Defense World ·  2022/12/25 02:21

Bone Biologics (OTC:BBLG – Get Rating) and Align Technology (NASDAQ:ALGN – Get Rating) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

骨生物製劑(OTC:BBLG-獲得評級)和對齊技術(NASDAQ:ALGN-獲得評級)都是醫療公司,但哪個投資更好?我們將根據兩家公司的機構所有權,分析師建議,估值,盈利能力,風險,股息和收益的實力進行比較。

Valuation & Earnings

估值及收益

This table compares Bone Biologics and Align Technology's revenue, earnings per share (EPS) and valuation.

此表格比較骨生物製劑和 Align Technology 的收入、每股收益 (EPS) 和估值。

Get
取得
Bone Biologics
骨生物製劑
alerts:
警報:
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bone Biologics N/A N/A -$1.61 million N/A N/A
Align Technology $3.95 billion 4.02 $772.02 million $6.47 31.48
總收入 價格/銷售比率 淨收入 每股盈利 市盈比率
骨生物製劑 N/A N/A -一百六十一萬元 N/A N/A
對齊技術 三百九十五億美元 4.02 二億七千二百二十萬美元 6.47 美元 31.48

Align Technology has higher revenue and earnings than Bone Biologics.

對齊科技比骨生物製劑具有更高的收入和收益。

Volatility & Risk

波動性和風險

Bone Biologics has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.
骨生物製劑的測試值為 0.11,表明其股價比標普 500 少 89% 的波動性。相比之下,對齊技術的測試版為 1.65,表明其股價比標普 500 的波動性高 65%。

Profitability

盈利

This table compares Bone Biologics and Align Technology's net margins, return on equity and return on assets.

此表格比較了骨生物製劑和 Align Technology 的淨利潤、權益回報率和資產回報率。

Net Margins Return on Equity Return on Assets
Bone Biologics N/A 7,587.33% 7,258.20%
Align Technology 13.22% 14.39% 8.89%
淨利潤 權益回報率 資產回報率
骨生物製劑 N/A 7,587.33% 7,258.20%
對齊技術 13.22% 14.39% 8.89%

Analyst Ratings

分析師評級

This is a summary of recent recommendations for Bone Biologics and Align Technology, as provided by MarketBeat.

這是由 MarketBeat 提供的有關骨生物製劑和對齊技術的最近建議的摘要。

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bone Biologics 0 0 1 0 3.00
Align Technology 1 0 7 0 2.75
銷售評級 保留評分 購買評級 強大的買入評級 評級分數
骨生物製劑 0 0 1 0 3.00
對齊技術 1 0 7 0 2.75

Bone Biologics currently has a consensus target price of $2.25, suggesting a potential upside of 971.43%. Align Technology has a consensus target price of $298.00, suggesting a potential upside of 46.32%. Given Bone Biologics' stronger consensus rating and higher probable upside, research analysts plainly believe Bone Biologics is more favorable than Align Technology.

骨生物製劑目前的共識目標價格為 2.25 美元,表明潛在的上行空間為 971.43%。對齊技術的共識目標價格為 298.00 美元,表明潛在的上行空間為 46.32%。鑑於骨生物學的更強大的共識評級和更高的可能上漲空間,研究分析師清楚地認為骨生物製劑比 Align Technology 更有利。

Insider and Institutional Ownership

內幕和機構所有權

7.6% of Bone Biologics shares are owned by institutional investors. Comparatively, 84.9% of Align Technology shares are owned by institutional investors. 71.5% of Bone Biologics shares are owned by insiders. Comparatively, 0.6% of Align Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

7.6% 的骨生物製劑股份由機構投資者擁有。相比之下,對齊科技股份的 84.9% 由機構投資者擁有。71.5% 的骨生物製劑股份由內部人士擁有。相比之下,對齊技術股份的 0.6% 由內部人士擁有。強大的機構所有權表明,對沖基金,捐贈基金和大型資金經理認為股票將在長期內優於市場。

Summary

摘要

Align Technology beats Bone Biologics on 6 of the 11 factors compared between the two stocks.

對齊技術在兩個股票之間的 6 個因素中的 11 個因素中擊敗了骨生物製劑。

About Bone Biologics

關於骨生物製劑

(Get Rating)

(取得評分)

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

骨生物製劑公司是一家醫療器械公司,專注於使用重組人類蛋白質在脊柱融合中進行骨骼再生。該公司的 NELL-1/DBX 是一種組合產品,它是一種骨刺激性重組蛋白質,可針對骨骼再生提供針對目標的特定控制。它正在開發用於骨架成熟患者的脊柱融合手術的 NELL-1/DBX 融合裝置,用於從 L4-S1 的一個級別上進行退行性椎間盤疾病。該公司的平台技術在脊柱外科,骨科,一般骨科,整形重建,神經外科,介入放射學和運動醫學等外科專科領域的應用。它與加州大學洛杉磯分校技術開發小組簽訂了許可協議,以開發和商業化 NELL-1 用於脊柱融合應用。該公司成立於 2004 年,總部位於馬薩諸塞州伯靈頓。

About Align Technology

關於對齊技術

(Get Rating)

(取得評分)

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.

Align Technology, Inc. 是一家醫療器材公司,為牙齒矯正醫生和全科醫生設計、製造和銷售 Invisalign 隱適美透明牙套和 iTerO 口腔掃描器和服務,以及修復和美容牙科。它分為兩個部分,透明對齊器;以及掃描器和服務。Clear Alignner 部分包括全面的產品,包括隱適美隱適美全面治療,以滿足青少年患者的正畸需求,例如下頜進步,合規指標和牙齒噴發補償;隱適美第一階段 I 期和 Invisalign 第一階段綜合 2 期套餐,適用於一般七歲到十歲的年輕患者,這是初生/嬰兒和永久牙齒的混合物。該細分市場的非全面性產品包括 Invisalign 中度、精簡版和快遞套餐和 Invisalign Go; 和非案例產品包括保留產品、Invisalign 培訓費用和附屬產品的銷售,例如清潔材料,以及在治療過程中牙科專業人士使用的調整工具。掃描器和服務部門提供 iTerO 掃描器,這是一個單一的硬體平台,提供修復或牙齒矯正程序的軟體選項;適用於一般醫生牙醫、修復牙科醫生、牙周醫師和口腔外科醫生的修復軟體;以及適用於數位記錄儲存、矯正診斷以及印刷模型和固定器製作的正畸醫生軟體。該分部還提供計算機輔助設計和計算機輔助製造服務;輔助產品,例如用於魔杖的一次性套筒;iTero 模型和模具;第三方掃描儀和數字掃描儀隱形結果模擬器,Invisalign Invisalign 進度評估工具;和延時技術,醫生允許或從業人員比較患者的歷史 3D 掃描儀。該公司在美國,瑞士,中國和國際上銷售其產品。艾齊科技有限公司成立於 1997 年,總部位於亞利桑那州坦佩。

Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

每日接收骨生物製劑的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收骨生物製劑及相關公司的最新新聞和分析師評級的簡要每日摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論